Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels
This article was originally published in The Tan Sheet
Executive Summary
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.
You may also be interested in...
Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn
OTC proton pump inhibitors should carry a warning that the products do not eliminate risks of esophageal cancer from persistent heartburn, says the Esophageal Cancer Action Network in a citizen petition to US FDA. FDA should “immediately” require the warning, which should be bold and prominent.
Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn
OTC proton pump inhibitors should carry a warning that the products do not eliminate risks of esophageal cancer from persistent heartburn, says the Esophageal Cancer Action Network in a citizen petition to US FDA. FDA should “immediately” require the warning, which should be bold and prominent.
UK Notes PPI Dermatosis Risk: Will FDA Make Similar Communication?
The UK drug regulator announces “a very low risk” of sub-acute cutaneous lupus erythematosus from use of PPIs, which are available there with the same ingredients approved for use in the US in products available OTC and RX – esomeprazole, lansoprazole and omeprazole – and Rx only, pantoprazole and rabeprazole.